Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
RVTY gained 13.3% after Q2 adjusted EPS of $1.41 beat the $1.23 consensus on $730 million of revenue, prompting higher full-year revenue and profit guidance. Diagnostics, AI-enabled drug discovery and the SuperFlex launch add product momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash generation ⢠Moderate leverage risk ⢠Margin pressure RVTY's strong cash flow and adequate liquidity are offset by softer margins, moderate leverage, intangible-heavy assets, and increasingly expensive valuationâwarranting a cautious stance.
Price Behavior
Key Price Behavior Insights: ⢠Strong uptrend ⢠Overbought momentum ⢠Breakout test Support Level: $128.00â$129.00; stronger support $123.00â$125.00 Resistance Level: $130.90â$131.00 RVTY is in a strong last-month uptrend but, with RSI near 73 and resistance at $130.90â$131.00, investors should watch for a breakout or short-term pullback toward $128.00â$129.00.
Sentiment & News
Key News Insights: ⢠Raised outlook ⢠Diagnostics strength ⢠Valuation risks Revvity's stronger earnings, raised outlook, and diagnostics momentum support a positive near-term view, though premium valuation and software risks warrant caution.
AI Summary
RVTY is a cash-generative recovery and research-platform story, but at ~54â62x earnings the stock already prices in diagnostics, pharma/biotech, and AI-workflow execution that has yet to translate into meaningful organic growth or higher ROIC; wait for sustained growth/margin proof or a better entry point, as leverage and valuation leave little room for merely adequate results.
Description
Revvity, Inc. supplies instruments, reagents, software and laboratory services across diagnostics, life sciences research and applied markets globally through two reporting segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions unit sells research tools, informatics, imaging and analytical technologies used in academic and industrial research, environmental testing, food and agricultural applications, and industrial process monitoring, while the Diagnostics segment provides assay platforms, tests and supporting software for genetic and infectious disease screening and for genomic workflows in oncology and drug discovery. The company serves pharmaceutical and biotech firms, clinical and public health laboratories, academic institutions, healthcare providers and government agencies; it was founded in 1937, is headquartered in Waltham, Massachusetts, and changed its name from PerkinElmer in April 2023.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 1 | Sep 8 | RVTY | Revvity, Inc. | RVTY gained 13.3% after Q2 adjusted EPS of $1.41 beat the $1.23 consensus on $730 million of revenue, prompting higher full-year revenue and profit guidance. Diagnostics, AI-enabled drug discovery and the SuperFlex launch add product momentum. | Closed | +0.4% |